網膜中心静脈閉塞症の黄斑浮腫に対するベバシズマブ硝子体注射の長期予後にかかわる因子

Factors involved in the long-term outcome of intravitreal bevacizumab for central retinal vein occlusion with macular edema

要約　目的：網膜中心静脈閉塞症の黄斑浮腫（CRVO-ME）に対するベバシズマブ硝子体注射（IVB）の治療成績の報告。対象と方法：対象は2008～2011年に初回IVBを行ったCVO-ME 14例14眼で男性6眼，女性8眼，平均年齢68.9歳。12か月後の視力，中心窩網膜厚（CRT），投与回数に関与する因子を検討した。結果：平均視力は改善（p＜0.05），平均CRTは減少（p＜0.01），平均投与回数は3.0回で，4回以上の群は高齢で，側副血行路（RCC）の出現頻度が高かった（p＜0.05）。結論：CVO-MEに対するIVBは1年後の視力改善に有効で，高齢とRCC出現はIVB回数を増加させる因子である。

Abstract.　Purpose：To report factors involved in the long-term outcome of intravitreal bevacizumab for central retinal vein occlusion（CRVO）with macular edema. Cases and Method：This study was made on 14 eyes of 14 cases who received intravitreal injection of bevacizumab for CRVO with macular edema in the past 4 years. The series comprised 6 males and 8 females. The age averaged 69 years. They were followed up for 12 months. Results：Averaged visual acuity improved significantly（p＜0.05）. Central foveal thickness decreased significantly（p＜0.01）. Treatment was repeated for an average of 3.0 times. Cases who received treatment for 4 times or more were advanced in age and showed higher rate of formation of collateral vessels（p＜0.05）. Conclusion：Intravitreal bevacizumab was effective for CRVO with macular edema after 12 months. Treatment had to be repeated more often in cases of advanced age and in eyes with formation of retinociliary collaterals.